In:
Oncology, S. Karger AG, Vol. 83, No. 5 ( 2012), p. 241-247
Abstract:
〈 b 〉 〈 i 〉 Purpose: 〈 /i 〉 〈 /b 〉 This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras 〈 i 〉 (KRAS) 〈 /i 〉 gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC). 〈 b 〉 〈 i 〉 Patients: 〈 /i 〉 〈 /b 〉 Overall, 119 patients bearing a 〈 i 〉 KRAS 〈 /i 〉 mutation in codon 12 were evaluated. All patients received cetuximab-based first-line chemotherapy within the Central European Cooperative Oncology Group (CECOG), AIO KRK-0104 or AIO KRK-0306 trials. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Patients with 〈 i 〉 KRAS 〈 /i 〉 codon 12 mutant mCRC showed a broad range of outcome when treated with cetuximab-based first-line regimens. Patients with tumors bearing a 〈 i 〉 KRAS 〈 /i 〉 p.G12D mutation showed a strong trend to a more favorable outcome compared to other mutations (overall survival 23.3 vs. 14–18 months; hazard ratio 0.66, range 0.43–1.03). An interaction model illustrated that 〈 i 〉 KRAS 〈 /i 〉 p.G12C was associated with unfavorable outcome when treated with oxaliplatin plus cetuximab. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 The present analysis suggests that 〈 i 〉 KRAS 〈 /i 〉 codon 12 mutation may not represent a homogeneous entity in mCRC when treated with cetuximab-based first-line therapy.
Type of Medium:
Online Resource
ISSN:
0030-2414
,
1423-0232
Language:
English
Publisher:
S. Karger AG
Publication Date:
2012
detail.hit.zdb_id:
1483096-6
detail.hit.zdb_id:
250101-6
Bookmarklink